Agent- and Dose-Specific Intestinal Obstruction Safety of GLP-1 Receptor Agonists and SGLT2 Inhibitors: A Network Meta-Analysis of Randomized Trials
Authors:
- Jiann-Jy ChenJCJiann-Jy Chen
- Chih-Wei HsuCHChih-Wei Hsu
- Chao-Ming HungCHChao-Ming Hung
- Mein-Woei SuenMein-Woei Suen
- Hung-Yu WangHWHung-Yu Wang
- Wei-Chieh YangWYWei-Chieh Yang
- Brendon StubbsBSBrendon Stubbs
- Yen-Wen ChenYCYen-Wen Chen
- Tien-Yu ChenTCTien-Yu Chen
- Wei-Te LeiWLWei-Te Lei
- Andre F. CarvalhoACAndre F. Carvalho
- Shih-Pin HsuSHShih-Pin Hsu
Open Access
- 7 January 2026
- journal article
- network meta-analysis
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (2) , 608
Abstract
Glucagon-like peptide-1 (GLP-1) receptor agonists and sodium–glucose cotransporter-2 (SGLT2) inhibitors have reshaped pharmacological management of type 2 diabetes, but emerging safety signals suggest a possible association with intestinal obstruction. Because many candidates for these agents already harbor risk factors for ileus and bowel obstruction, clarifying agent- and dose-specific gastrointestinal safety is clinically important. We aimed to re-evaluate the risk of intestinal obstruction across individual GLP-1 receptor agonists and SGLT2 inhibitors, with particular attention to dose stratification. We systematically searched eight databases through 21 January 2025 to identify randomized controlled trials (RCTs) comparing GLP-1 receptor agonists or SGLT2 inhibitors with placebo or active comparators in adults. The primary outcome was incident intestinal obstruction (small or large bowel). A frequentist random-effects network meta-analysis estimated odds ratios (ORs) with 95% confidence intervals (CIs) across drugs and dose tiers; Bayesian models and surface under the cumulative ranking (SUCRA) metrics were used for sensitivity analyses and treatment ranking. Risk of bias and certainty of evidence were assessed with standard Cochrane and GRADE-adapted tools. Fifty RCTs (47 publications; 192,359 participants) met inclusion criteria. Overall, canagliflozin use was associated with a higher incidence of intestinal obstruction than control therapies (OR 2.56, 95% CI 1.01–6.49), corresponding to an absolute risk difference of 0.15% and a number needed to harm of 658. High-dose canagliflozin (300 mg/day) showed the clearest signal (OR 3.42, 95% CI 1.08–10.76). In contrast, liraglutide was associated with a lower risk of intestinal obstruction (OR 0.44, 95% CI 0.24–0.81), with an absolute risk reduction of 0.34% and a number needed to treat of 295. No other GLP-1 receptor agonist or SGLT2 inhibitor demonstrated a statistically significant increase in obstruction risk. Frequentist and Bayesian analyses yielded concordant estimates and rankings. From a randomized-trial perspective, intestinal obstruction risk is not elevated for most GLP-1 receptor agonists and SGLT2 inhibitors. A dose-dependent safety signal was observed only for high-dose canagliflozin, whereas liraglutide may confer a protective effect. These findings refine gastrointestinal safety profiles for modern antidiabetic agents and may inform perioperative bowel management, drug selection, and dose optimization in patients at risk for ileus or adhesive obstruction.Keywords
This publication has 191 references indexed in Scilit:
- Adverse Events in Studies of Classic PsychedelicsJAMA Psychiatry, 2024
- Tirzepatide for Weight Reduction in Chinese Adults With ObesityJAMA, 2024
- Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With ObesityJAMA, 2024
- Tirzepatide vs Insulin Lispro Added to Basal Insulin in Type 2 DiabetesJAMA, 2023
- Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 DiabetesJAMA, 2022
- Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without DiabetesJAMA, 2022
- Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or ObesityJAMA, 2021
- Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or ObesityJAMA, 2021
- Effect of Additional Oral Semaglutide vs Sitagliptin on Glycated Hemoglobin in Adults With Type 2 Diabetes Uncontrolled With Metformin Alone or With SulfonylureaJAMA, 2019
- Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 DiabetesJAMA, 2015